Michael Vasconcelles is Head of Research and Dev. at Day One Biopharmaceuticals, Inc. (DAWN). They have made 1 open-market trade across 1 company since 2026, most recently 2026-02-17.
CIK 0001734755
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| DAWN | 7,125 | $153K |
| IMGN | 1,327 | $41K |
| Total | $195K |
Shares reported on the most recent Form 4, priced at the 2026-02-18 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| DAWN | SELL | 2026-02-17 | 2026-02-18 | $11.60 | $32K | -9.8% | +86.3% | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.